Selinexor in Combination With MTX+Ritu to Treat R/R CNSL

Selinexor in Combination With Methotrexate and Rituximab for Relapsed /Refractory Central Nervous System (CNS) Lymphoma

This is a single-arm and open-label study to explore X+MTX+Ritu (ATG-010, Methotrexate, Rituximab) regimen in Relapse refractory PCNSL patients. Approximately 30 patients will be enrolled in the study. In dose escalation phase, patients with Relapse refractory PCNSL will be treated with X+MTX+Ritu regimen and escalating doses of oral ATG-010 weekly in a 3+3 design. Then a phase 2 expansion at the recommended dose level based on phase 1b trial will be conducted to evaluate the efficacy, safety and tolerability.

Study Overview

• Status: Recruiting
• Conditions: Central Nervous System Lymphoma
• Intervention / Treatment: Drug: Selinexor; Drug: Rituximab; Drug: Methotrexate

Detailed Description

In dose escalation phase, patients with Relapse refractory PCNSL will be treated with X+MTX+Ritu regimen （Methotrexate 3.5 g/m2, d1; Rituximab 375 mg/m2, d0）and escalating doses of oral ATG-010 weekly in a 3+3 design. ATG-010 dose level (DL) 1, 2 and 3 are 60, 80 and 100mg respectively respectively on day 1,8,15,22 for 28-days cycle.

The phase 2 expansion at the recommended dose level based on phase 1b trial. The total 6 cycles, 28 days per cycle . And, Subjects participating in the study will undergo a screening period（up to 21days）, a treatment period, and a follow-up period. The screening period is a maximum of 21 days before treatment period, And will be followed by 6 cycles of combination treatment（28 days per cycle）.

partial remission(PR) patients after induction treatment will continue ATG-010 maintenance up to 1 year or until disease progression, intolerable toxicity, death.

• Study Type: Interventional
• Enrollment (Estimated): 30
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Tong Chen, Ph.D; Phone Number: +862152887102; Email: chentong@fudan.edu.cn
• Study Contact Backup: Name: Yuan Yan, Ph.D; Phone Number: +862152888283; Email: yuanyan@fudan.edu.cn

Study Locations

• China
  • Anhui
    • Hefei, Anhui, China
      • Not yet recruiting
      • The First Affiliated Hospital of Anhui Medical University
      • Contact: Jian Ge, Ph.D
  • Beijing
    • Beijing, Beijing, China
      • Not yet recruiting
      • Beijing Tiantan Hospital, Capital Medical University
      • Contact: Wenbin Li, Ph.D; Phone Number: +8615301377998; Email: neure55@126.com
  • Fujian
    • Fuzhou, Fujian, China
      • Not yet recruiting
      • The First Affiliated Hospital of Fujian Medical University
      • Contact: Zhiyong Zeng, Ph.D
  • Henan
    • Zhengzhou, Henan, China, 450052
      • Not yet recruiting
      • Oncology Department of The First Affiliated Hospital of Zhengzhou University
      • Contact: Mingzhi Zhang, PhD; Phone Number: 13838565629; Email: mingzhi_zhang@126.com
      • Principal Investigator: Mingzhi Zhang, PhD
  • Shanghai
    • Shanghai, Shanghai, China, 200040
      • Recruiting
      • Department of Hematology, Huashan Hospital, Fudan University
      • Contact: Tong Chen; Phone Number: +862152887102; Email: chentong@fudan.edu.cn
      • Contact: Yan Yuan; Phone Number: +862152888283; Email: yuanyan@fudan.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients must meet all of the following inclusion criteria to be eligible to enroll in this study:

  1. Participants must be able to understand and be willing to sign a written informed consent document.
  2. Men and woman who are 18-75 years old on the day of consenting to the study.
  3. Histologically documented PCNSL and SCNSL secondary to histologically documented systemic diffuse large B-cell lymphoma (DLBCL).
  4. Patients must have relapsed/refractory PCNSL or relapsed/refractory SCNSL.
  5. Patients must have response or remain stable disease for 2 months to prior methotrexate-based regimen.
  6. Patients who had prior autologous hematopoietic stem cell transplantation are eligible.
  7. Patients with parenchymal lesions must have unequivocal evidence of disease progression on imaging (MRI of the brain or head CT) 28 days prior to cycle1 day 1(C1D1). For patients with leptomeningeal disease only, CSF cytology must document lymphoma cells.
  8. Participants must have an Eastern Cooperative Oncology Group performance status of 0-3.

  9. Participants must have adequate bone marrow and organ function shown by:

     1. Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L
     2. Platelets ≥ 75 x 10^9/L and no platelet transfusion within the past 14 days prior to study registration c Hemoglobin (Hgb) ≥ 8 g/dL and no red blood cell (RBC) transfusion within the past 14 days prior to study registration
  10. International Normalized Ratio (INR) ≤ 1.5 and PTT (aPTT) ≤ 1.5 times the upper limit of normal.
  11. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of normal.
  12. Serum bilirubin ≤ 1.5 times the upper limit of normal; or total bilirubin ≤ 3 times the upper limit of normal with direct bilirubin within the normal range in patients with well documented Gilbert Syndrome.
  13. Calculated creatinine clearance(CrCl)≥50ml/min using the Cockcroft-Gault equation or 24-hour urine collection.
  14. Life expectancy of > 3 months.

Exclusion Criteria:

1. Patients with SCNSL actively receiving treatment for extra-CNS disease are excluded.
2. Lymphoma patients with only intraocular involvement.
3. Pathological diagnosis of PCNSL is T-cell lymphoma.
4. Patients with disease progression within 6 months of prior methotrexate-containing regimen.
5. patients only had received stereotactic radiation therapy as prior treatment.
6. Patients have received chemotherapy, monoclonal antibodies or targeted anticancer therapy within 21 days or 5 half-lives, whichever is shorter, prior to C1D1.

7. Patients with active, unstable cardiovascular diseases, fits any of the following:

   1. myocardial infarction within 6 months prior to the study enrollment
   2. unstable angina within 3 months prior to the study enrollment
   3. Uncontrolled clinically-significant conduction abnormalities (e.g., ventricular tachycardia, ventricular fibrillation, etc.)
   4. Congestive heart failure (CHF) of New York Heart Association (NYHA) ≥ Grade 3
   5. Echocardiography showing left ventricular ejection fraction less than 50%
8. Uncontrolled active infection within 1 week prior to the first dose of study drug.
9. Known active hepatitis B, or C infection or HIV infection; Note: Hepatitis B virus (HBV) surface antigen (HBsAg) and or hepatitis B core antibody-positive but undetectable HBV DNA or Hepatitis C virus (HCV) antibody positive but hepatitis C virus RNA undetectable are allowed.
10. Active GI dysfunction interfering with the ability to swallow tablets, or any GI dysfunction that could interfere with absorption of study treatment.
11. Prior exposure to a selective inhibitor of nuclear export(SINE) compound, including selinexor.
12. Serious, active psychiatric, or medical conditions which, in the opinion of the Investigator, could interfere with study treatment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: X-MTX-Ritu; Escalating doses of oral ATG-010 weekly in a 3+3 design. ATG-010 dose level (DL) 1, 2 and 3 are 60, 80 and 100mg respectively respectively on day 1,8,15,22 for 28-days cycle.and the phase 2 expansion at the recommended dose level based on phase 1b trial. And， Methotrexate 3.5 g/m2, d1 and Rituximab 375 mg/m2, d0, 28-days cycle.The total 6 cycles, 28 days per cycle.

Drug: Selinexor; Selinexor dose escalation: 60,80,100mg respectively on day 1,8,15,22 for 28 days cycles, and dose expansion at the RP2D of Selinexor. PR patients after induction treatment will continue ATG-010 maintenance up to 1 year or until disease progression, intolerable toxicity, death.; Other Names: ATG-010; Drug: Rituximab; Rituximab 375 mg/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.; Other Names: RiTUXimab Injection; Drug: Methotrexate; high-dose Methotrexate 3.5 g/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.; Other Names: MTX

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dose Escalation: Maximum Tolerated Dose (MTD) of Selinexor	The MTD will be determined by study definition as the highest dose level without significant safety and tolerability concern.	Assessed from the date of first dose of study treatment to the first cycle ends (maximum 21days)
Dose Escalation: Recommended Phase 2 Does (RP2D) of Selinexor	The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for the dose expansion arms, based on safety, tolerability, efficacy data collected during the dose escalation portion of the study	Assessed from the date of first dose of study treatment to the first cycle ends (maximum 21days)
Objective Response Rate (ORR)	ORR is defined as the proportion of patients with a best response of Complete remission (CR) or Unconfirmed(CRu), or PR during induction therapy	Cycle 1 Day 1 (each cycle consists of maximum 21 days) until a CR, CRu or PR (up to 18 cycles(each cycle is 21 days)).

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Duration of Response (DOR)	Duration from the first observation of at least PR to time of progressive disease(PD), or deaths due to disease progression,whichever occurs first	From first dose of study drug administration to end of treatment, up to 18 cycles(each cycle is 21 days)
Overall Survival (OS)	Occurrence of death regardless of cause	up to 12 months
Progression-Free Survival (PFS)	Duration from start of study treatment to PD or death (regardless of cause), whichever comes first	up to 12 months
Number of Participants with Adverse Events	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)	From first dose of study drug administration to end of treatment (up to 18 cycles(each cycle is 21 days))

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Gene mutations and frequency of 475 gene and whole exon	The types of gene mutations and frequency of tumor are measured by whole exon sequencing via NGS(next-generation sequencing).	At baseline
The concentration of interleukin-10(IL-10)，interleukin-6(IL-6)，CXCL-13 cytokine in cerebrospinal fluid(CSF)	The levels of cytokines will be analyzed by flow cytometry	At the baseline, day 1 at cycle 3, 5 (21 days/cycle), and every 3 months in the maintenance stage (up to 1 year))
Circulating tumor DNA (ctDNA) in the CSF	The levels of ctDNA will be analyzed by next-generation sequencing.	At the baseline, day 1 at cycle 3, 5 (21days/cycle), and every 3 months in the maintenance stage (up to 1 year))

Collaborators and Investigators

• Sponsor: Tong Chen
• Collaborators: Antengene Corporation
• Investigators: Principal Investigator: Tong Chen, Ph.D, Huashan Hospital

Study record dates

Study Major Dates

• Study Start (Actual): August 3, 2023
• Primary Completion (Estimated): June 30, 2026
• Study Completion (Estimated): December 31, 2026

Study Registration Dates

• First Submitted: January 4, 2023
• First Submitted That Met QC Criteria: January 15, 2023
• First Posted (Actual): January 26, 2023

Study Record Updates

• Last Update Posted (Actual): September 21, 2023
• Last Update Submitted That Met QC Criteria: September 20, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Keywords: Selinexor; ATG-010; Relapse refractory; Primary Central Nervous System Lymphoma（PCNSL）; Secondary Central Nervous System Lymphoma（SCNSL）
• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Antirheumatic Agents; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Antineoplastic Agents, Immunological; Dermatologic Agents; Reproductive Control Agents; Abortifacient Agents, Nonsteroidal; Abortifacient Agents; Folic Acid Antagonists; Rituximab; Methotrexate
• Other Study ID Numbers: KY2022-881

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes